Crescent Biopharma, Inc. (CBIO) Stock

NASDAQ: CBIOHealthcare company in the biotechnology industry, based in Waltham, MA.

Crescent Biopharma stock price chart

CBIO interactive chart →

CBIO stock quote & key statistics

Crescent Biopharma earnings per share

Income →
Earnings per share

Crescent Biopharma revenue & net income

Income →
RevenueNet income

Crescent Biopharma annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$10.8M-$153.9M-$27.49
FY2023$10,000-$36.9M-$0.58
FY2022$75,000-$46.7M-$0.88
FY2021$1.2M-$63.4M-$1.23

Fiscal year ending December 31. Source: company filings via EODHD.

About Crescent Biopharma, Inc.

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Crescent Biopharma stock FAQ

What is the Crescent Biopharma stock ticker symbol?

Crescent Biopharma, Inc. trades on the NASDAQ under the ticker symbol CBIO.

What sector and industry is Crescent Biopharma in?

Crescent Biopharma, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Crescent Biopharma have?

Crescent Biopharma, Inc. has about 69 full-time employees.

What were Crescent Biopharma's revenue and earnings last fiscal year?

Crescent Biopharma reported revenue of $10.8M and net income of -$153.9M in fiscal 2025, with earnings per share of -$27.49. Revenue grew 108340.0% from the prior year.

Is Crescent Biopharma in the Russell 2000?

Yes. Crescent Biopharma, Inc. (CBIO) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Crescent Biopharma go public?

Crescent Biopharma stock began trading on January 10, 2014.

Russell 2000 Biotechnology stocks

All Russell 2000 →